AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common ...

AbbVie’s Rinvoq, meanwhile ... a follow-up to its 2015 infusion pump Duopa. With a non-surgical, continuous delivery system, the drug has the potential to “significantly expand use” beyond ...

The drug also represents the next generation of AbbVie's Parkinson's therapy offerings and a successor of sorts to the company's Duopa, which launched in 2015. Coverage for Medicare patients is ...

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

AbbVie cautions that these forward-looking statements ... It can deliver high levodopa doses similar to the amount provided by Duopa and it doesn’t require combination with oral drugs to achieve ...

AbbVie already sells another long-acting treatment called Duopa, which delivers carbidopa and levodopa in an intestinal gel form via a gastric tube and pump, but that requires a surgical procedure ...

About AbbVie Inc., Gilead Sciences and Inc. AbbVie Inc. discovers ... Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of ...

About AbbVie Inc. and Amgen Inc. AbbVie Inc. discovers ... Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in ...

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...